PE20161344A1 - Determinantes de respuesta del cancer a la inmunoterapia - Google Patents

Determinantes de respuesta del cancer a la inmunoterapia

Info

Publication number
PE20161344A1
PE20161344A1 PE2016000989A PE2016000989A PE20161344A1 PE 20161344 A1 PE20161344 A1 PE 20161344A1 PE 2016000989 A PE2016000989 A PE 2016000989A PE 2016000989 A PE2016000989 A PE 2016000989A PE 20161344 A1 PE20161344 A1 PE 20161344A1
Authority
PE
Peru
Prior art keywords
antigen
composition
determinants
immunotherapy
cancer
Prior art date
Application number
PE2016000989A
Other languages
English (en)
Inventor
Timothy Chan
Jedd Wolchok
Charen Alexandra Snyder
Vladimir Makarov
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of PE20161344A1 publication Critical patent/PE20161344A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a una composicion que comprende multiples neoepitopos caracterizados porque: a) comprenden una mutacion somatica; b) se unen al complejo mayor de histocompatibilidad de clase I del sujeto con un IC50 inferior o igual a 500 nM.; c) comprenden un tetrapeptido que es una region conservada entre los antigenos reconocido por un receptor de celulas T tal como AARA, ALLN, entre otros y d) comparten una secuencia de consenso con un antigeno de un agente infeccioso. Ademas comprende un inhibidor de puntos de control del sistema inmunitario tal como un anticuerpo o fragmento de union al antigeno de este que se une a un regulador de respuesta inmunitaria seleccionado de CTLA4, PD1, PD-L1 y OX40; tambien se refiera a un kit de deteccion. Dicha composicion es util en el tratamiento de cancer
PE2016000989A 2014-01-02 2014-12-23 Determinantes de respuesta del cancer a la inmunoterapia PE20161344A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461923183P 2014-01-02 2014-01-02
US201462066034P 2014-10-20 2014-10-20
US201462072893P 2014-10-30 2014-10-30

Publications (1)

Publication Number Publication Date
PE20161344A1 true PE20161344A1 (es) 2016-12-23

Family

ID=53494217

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000989A PE20161344A1 (es) 2014-01-02 2014-12-23 Determinantes de respuesta del cancer a la inmunoterapia

Country Status (15)

Country Link
US (1) US20160326597A1 (es)
EP (1) EP3090066A4 (es)
JP (1) JP2017504324A (es)
KR (1) KR20160102314A (es)
CN (1) CN106164289A (es)
AU (1) AU2014374020A1 (es)
BR (1) BR112016015399A2 (es)
CA (1) CA2935214A1 (es)
CL (1) CL2016001708A1 (es)
MX (1) MX2016008771A (es)
PE (1) PE20161344A1 (es)
PH (1) PH12016501329A1 (es)
RU (1) RU2707530C2 (es)
SG (2) SG11201605432RA (es)
WO (1) WO2015103037A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
CN106999582A (zh) 2014-11-13 2017-08-01 约翰·霍普金斯大学 检查点阻断和微卫星不稳定性
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
US20180133327A1 (en) * 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
CA2987730C (en) 2015-04-08 2020-02-18 Nantomics, Llc Cancer neoepitopes
US11421016B2 (en) * 2015-04-23 2022-08-23 Nantomics Llc Cancer neoepitopes
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CA3003251A1 (en) * 2015-10-12 2017-04-20 Nantomics, Llc Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
EP3362929B1 (en) * 2015-10-12 2020-08-12 Nantomics, LLC Viral neoepitopes and uses thereof
KR20180083327A (ko) * 2015-10-12 2018-07-20 난토믹스, 엘엘씨 바이러스성 암 네오에피토프를 위한 조성물 및 방법
CN108348588B (zh) * 2015-10-23 2023-01-13 诺华股份有限公司 用于导出视野中呈现的选定细胞的生物标志物阳性百分比值的方法
TWI733719B (zh) 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
US20190015491A1 (en) * 2016-01-08 2019-01-17 Vaccibody As Neoepitope rna cancer vaccine
US11585805B2 (en) 2016-02-19 2023-02-21 Nantcell, Inc. Methods of immunogenic modulation
JP2019509282A (ja) * 2016-02-29 2019-04-04 ファウンデーション・メディシン・インコーポレイテッド 癌の治療方法
CN109196121B (zh) 2016-02-29 2022-01-04 基因泰克公司 用于癌症的治疗和诊断方法
US20190080044A1 (en) * 2016-03-15 2019-03-14 Repertoire Genesis Incorporation Monitoring and diagnosis for immunotherapy, and design for therapeutic agent
PT3429618T (pt) * 2016-03-16 2024-04-02 Amal Therapeutics Sa Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina
EP3468600A4 (en) * 2016-06-10 2019-11-13 IO Therapeutics, Inc. RETINOID COMPOUNDS AND RELECTIVE REXINOIDS OF THE RECEPTOR AND IMMUNE MODULATORS FOR IMMUNOTHERAPY OF CANCER
WO2018005276A1 (en) * 2016-06-29 2018-01-04 The Johns Hopkins University Neoantigens as targets for immunotherapy
WO2018055060A1 (en) 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
EP3516081A4 (en) * 2016-09-23 2020-07-29 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER REACTION TO IMMUNOTHERAPY
CN110418851A (zh) * 2016-10-06 2019-11-05 基因泰克公司 癌症的治疗和诊断方法
AU2017367696A1 (en) 2016-12-01 2019-06-20 Nant Holdings Ip, Llc Tumor antigenicity processing and presentation
US11480572B2 (en) 2016-12-16 2022-10-25 Nantbio, Inc. Live cell imaging systems and methods to validate triggering of immune response
WO2018132753A1 (en) * 2017-01-13 2018-07-19 Nantbio, Inc. Validation of neoepitope-based treatment
CA3050109A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
WO2018146128A1 (en) * 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
CN110431238A (zh) * 2017-03-17 2019-11-08 南托米克斯有限责任公司 cfRNA的液体活检
US20210101980A1 (en) * 2017-03-31 2021-04-08 Bristol-Myers Squibb Company Methods of treating tumor
JP2020522480A (ja) 2017-06-02 2020-07-30 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 個別化された犬用癌ワクチンを作製する方法
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
AU2018338441A1 (en) * 2017-09-25 2020-04-09 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
WO2019075468A1 (en) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company TUMOR TREATMENT METHODS
WO2019090156A1 (en) 2017-11-03 2019-05-09 Guardant Health, Inc. Normalizing tumor mutation burden
CN111566484A (zh) * 2017-11-09 2020-08-21 宾夕法尼亚大学董事会 细胞外囊泡蛋白及其在癌症诊断、预测对疗法的反应和治疗中的用途
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
CA3067229A1 (en) * 2017-12-01 2019-06-06 Illumina, Inc. Methods and systems for determining somatic mutation clonality
CN108009400B (zh) * 2018-01-11 2018-07-06 至本医疗科技（上海）有限公司 全基因组肿瘤突变负荷预测方法、设备以及存储介质
US11414698B2 (en) * 2018-03-22 2022-08-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi Method of quantifying mutant allele burden of target gene
EP3784688A2 (en) 2018-04-26 2021-03-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
AU2019310041A1 (en) 2018-07-23 2021-02-04 Guardant Health, Inc. Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
CN112930569A (zh) 2018-08-31 2021-06-08 夸登特健康公司 无细胞dna中的微卫星不稳定性检测
CN109371005B (zh) * 2018-11-12 2022-09-30 上海市东方医院（同济大学附属东方医院） 一种hla-0201限制性padi4表位多肽及其应用
CN113194995A (zh) * 2018-12-12 2021-07-30 免疫医疗有限责任公司 基于血液的肿瘤突变负荷预测非小细胞肺癌的总存活
JP2022525487A (ja) * 2019-04-05 2022-05-17 イルミナ インコーポレイテッド Ｈｌａ多様性の定量的スコア
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
NL2024107B1 (en) * 2019-10-26 2021-07-19 Vitroscan B V Compositions for Patient Specific Immunotherapy
CN111088349B (zh) * 2020-02-14 2023-04-28 深圳市宝安区妇幼保健院 Kir3dl1基因分型引物组及其应用
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
US20240192195A1 (en) * 2021-04-10 2024-06-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. A multiomic approach to modeling of gene regulatory networks in multiple myeloma
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
US9222938B2 (en) * 2001-12-04 2015-12-29 Michael Tainsky Neoepitope detection of disease using protein arrays
US7696175B2 (en) * 2004-10-29 2010-04-13 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
KR102447139B1 (ko) * 2010-05-14 2022-09-23 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer

Also Published As

Publication number Publication date
EP3090066A4 (en) 2017-08-30
SG10201805674YA (en) 2018-08-30
PH12016501329A1 (en) 2016-10-03
CN106164289A (zh) 2016-11-23
WO2015103037A3 (en) 2015-11-05
US20160326597A1 (en) 2016-11-10
RU2016131207A (ru) 2018-02-07
JP2017504324A (ja) 2017-02-09
CA2935214A1 (en) 2015-07-09
AU2014374020A1 (en) 2016-08-18
CL2016001708A1 (es) 2017-03-17
KR20160102314A (ko) 2016-08-29
EP3090066A2 (en) 2016-11-09
WO2015103037A2 (en) 2015-07-09
BR112016015399A2 (pt) 2017-10-24
MX2016008771A (es) 2016-12-20
RU2016131207A3 (es) 2018-06-22
SG11201605432RA (en) 2016-07-28
RU2707530C2 (ru) 2019-11-27

Similar Documents

Publication Publication Date Title
PE20161344A1 (es) Determinantes de respuesta del cancer a la inmunoterapia
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
CY1124190T1 (el) Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρηση
CO2019000946A2 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
PE20170125A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
CO2017007619A2 (es) Anticuerpos humanos contra glicoproteína del virus ébola
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
MX2022002364A (es) Anticuerpos anti-pd-l1.
PE20170289A1 (es) Anticuerpos anti tigit
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
SV2018005678A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
PE20161392A1 (es) Combinacion de lenalidomida y constructo de polipeptido, y sus usos
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
BR112016022727A2 (pt) ?imunorreceptores específicos de claudina-6 e epítopos de células t
MA40682B1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
EA201791270A1 (ru) Модифицированные april-связывающие антитела
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
AR085591A1 (es) Anticuerpos del antigeno carcinoembrionario humano (cea)